Tang Chunhai, Yang Zhenxiu, Chen Dongliang, Xie Qinghai, Peng Tao, Wu Jingzhan, Qi Songtao
Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou City, Guangdong Province, China; Department of neurosurgery, Second Affiliated Hospital,Guangxi Medical University, Nanning City,Guangxi Province, China.
Internal Medicine-Oncology, Tenth Affiliated Hospital, Guangxi Medical University, Qinzhou City, Guangxi Province, China.
Int J Biochem Cell Biol. 2017 Dec;93:25-31. doi: 10.1016/j.biocel.2017.08.010. Epub 2017 Aug 26.
Aberrant expression of miR-130a is usually found in cancer studies; however, the role of miR-130a has seldom been reported in glioma. We explored miR-130a's function and the underlying mechanism in glioma. It was found that miR-130a expression was significantly down-regulated in glioma tissues and cell lines. Overexpression of miR-130a decreased glioma cell growth and invasion both in vitro and in vivo. We identified the oncogene HMGB2 as a downstream target of miR-130a by using luciferase and western blot assays. Knockdown of HMGB2 mimicked the effect of miR-130a in glioma cells. Taken together, our study demonstrate that miR-130a may function as a tumor suppressor in glioma and suggest that miR-130a is a potential therapeutic target for glioma patients.
在癌症研究中，通常会发现miR-130a的异常表达；然而，miR-130a在胶质瘤中的作用鲜有报道。我们探究了miR-130a在胶质瘤中的功能及其潜在机制。研究发现，miR-130a在胶质瘤组织和细胞系中表达显著下调。过表达miR-130a在体外和体内均可降低胶质瘤细胞的生长和侵袭能力。通过荧光素酶和蛋白质免疫印迹分析，我们确定癌基因HMGB2是miR-130a的下游靶点。敲低HMGB2可模拟miR-130a对胶质瘤细胞的作用。综上所述，我们的研究表明miR-130a在胶质瘤中可能发挥肿瘤抑制作用，并提示miR-130a是胶质瘤患者潜在的治疗靶点。
